Eurofins Viracor: All Resources

BK Polyomavirus and thrombotic microangiopathy (TMA) are significant complications following stem cell transplantation, leading to serious health risks. In this presentation, Dr. Ben Laskin, Dr. Sonata Jodele, and Dr. Steve Kleiboeker discuss the current understanding of these conditions and highlight gaps in knowledge and treatment strategies. While advances have been made in diagnosing and managing BK virus-related complications, unmet needs remain in effectively addressing TMA. The presentation underscores the importance of continued research and collaboration to improve patient outcomes.

Accurate and early identification of patients at high-risk for severe acute graft versus host disease (aGVHD) and related complications has the potential to improve patient outcomes following allogeneic hematopoietic cell transplantation (alloHCT). High-risk patients can be preemptively treated for aGVHD prior to the onset of clinical disease while low-risk patients may potentially avoid unnecessary treatment. Validation of an interpretive algorithm based on serum ST2 and REG3α levels accurately predicts risks for allo-HCT patients when testing is performed at 7 days post-transplant, at the onset of aGVHD symptoms, and ≥ 1 week after the initiation of systemic therapy.

Chimeric antigen receptor (CAR) T cell therapy has transformed hematological cancer treatment, with six therapies now approved by the FDA. Four of these therapies (tisa-cel, axi-cel, brexu-cel, and liso-cel) target CD19 using single chain variable fragments (scFvs) derived from the heavy and light chain variable (VH and VL) regions of the monoclonal antibody FMC63.

For Hematology/Oncology patients the ExPeCT anti-CD19 (FMC63) CAR T assay provides interventional data which may provide information on the expansion and persistence of the genetically modified T-cells used as therapeutic treatment for specific lymphomas and leukemias (Chimeric Antigen Receptor T-cell therapy or CAR T). Eurofins Viracor has developed and validated a multiplexed quantitative real-time PCR (qPCR) assay targeting FMC63 for the longitudinal monitoring of CD19-directed CAR T-cell therapy.

This e-book presents a synopsis of how we operate, our services, and most importantly, our commitment to you and your patients. Viracor provides accurate results, exceptional turnaround times, and personalized guidance that puts you at the forefront of empowering the patient's healthcare decisions.

This webinar provides an in-depth exposé of the emergence of Candida species in the healthcare system. Highlighted topics include a comparative discussion on current diagnostic platforms, current and future therapy options, and the prevention of invasive candidiasis. This webinar aims to address the critical challenges posed by candidiasis in healthcare settings and equipping healthcare professionals with the knowledge and tools needed to effectively manage and combat it.

Transplant testing plays a vital role in improving outcomes for patients undergoing bone marrow or stem cell transplants. Eurofins offers comprehensive pre- and post-transplant testing, including advanced HLA typing, infectious disease monitoring, and graft-versus-host disease (GVHD) detection. These services enable healthcare providers to optimize patient care by minimizing complications such as graft rejection and infections. With cutting-edge diagnostics and personalized testing solutions, Eurofins Viracor is committed to enhancing transplant success and supporting patients and healthcare teams.